Add Yahoo as a preferred source to see more of our stories on Google. It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes ...
Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced in a press release that only around one in four patients with seborrheic ...
Please provide your email address to receive an email when new articles are posted on . On Dec. 16, 2023, roflumilast foam 0.3% was FDA-approved for the treatment of seborrheic dermatitis. The results ...
WESTLAKE VILLAGE, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
After 8 weeks, eight out of ten people with seborrheic dermatitis saw their symptoms cleared or improved with once-daily treatment with roflumilast 0.3% foam, according to the results of the phase 3 ...
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...
Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...
This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let's talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...
CRUSTY skin isn’t something you usually bring up at the dinner table, but a lot of us are dealing with skin that flakes, ...
New York — Seborrheic dermatitis (SD) is a common and shared disorder across populations, but it is the third most common dermatologic complaint that Black individuals bring to the dermatologist and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results